Results 131 to 140 of about 419,175 (164)

STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials

, 2004
David Langleben, Tommy A. Brock, Richard A. F. Dixon, Robyn J. Barst   +3 more
openalex   +1 more source

End points and clinical trial designs in pulmonary arterial hypertension

, 2004
Marius M. Hoeper, Ronald J. Oudiz, Andrew J. Peacock, Victor F. Tapson, Sheila G. Haworth, Adaani Frost, Adam Torbicki   +6 more
openalex   +1 more source

PGI2-Aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction [PDF]

, 1993
Habazettl, H., Messmer, Konrad, Welte, M., Zwißler, Bernhard   +3 more
core   +1 more source

Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral Therapy

, 2004
Jean‐Philippe Zuber, Alexandra Calmy, John Evison, Barbara Hasse, Véronique Schiffer, Thomas Wagels, Reto Nüesch, Lorenzo Magenta, Bruno Ledergerber, Rolf Jenni, Rudolf Speich, Milos Opravil   +11 more
openalex   +1 more source

1123-188 Role of amiodipine in preventing and reversing monocrotaline-induced pulmonary arterial hypertension in rats

, 2004
Eiichiro Mawatari, Minoru Hongo, Akio Sakai, Ruan Zonghai, Fumiaki Ogiwara, Noboru Watanabe, Yuichi Kamiyoshi, Osamu Kinoshita, Keishi Kubo   +8 more
openalex   +1 more source

Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells

, 2005
Yidan Zhao, David W. Courtman, Yupu Deng, Lakshmi Kugathasan, Qiuwang Zhang, Duncan J. Stewart   +5 more
openalex   +1 more source

Successful preoperative bridge with extracorporeal membrane oxygenation in three neonates with D-transposition of the great vessels and pulmonary hypertension [PDF]

, 2018
Gazit, Avihu Z, McBride, Mary E, Said, Ahmed S   +2 more
core   +1 more source

A promise to save 100,000 trauma patients.

, 2013
Horton, Richard, Krug, Etienne, Mersch, Jeannot, Piot, Peter, Roberts, Ian, Shakur, Haleema   +5 more
core   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.

New England Journal of Medicine, 2023
BACKGROUND Pulmonary arterial hypertension is a progressive disease involving proliferative remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated morbidity and mortality remain high.
M. Hoeper, D. Badesch, H. Ghofrani, J. Gibbs, M. Gomberg-Maitland, V. McLaughlin, I. Preston, R. Souza, A. Waxman, E. Grünig, G. Kopeć, G. Meyer, K. Olsson, Stephan Rosenkranz, Yayun Xu, B. Miller, Marcie Fowler, J. Butler, J. Koglin, J. de Oliveira Pena, M. Humbert   +20 more
semanticscholar   +1 more source

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Journal of the American Medical Association (JAMA), 2022
Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US.
N. Ruopp, B. Cockrill
semanticscholar   +1 more source